10-Q: NextCure Inc. Reports Q3 2024 Results, Prioritizes Pipeline and Extends Cash Runway

NextCure Inc. announced its third quarter 2024 results, highlighting a strategic pipeline prioritization and a cash runway extended into the second half of 2026.

Summary

• NextCure, Inc., a clinical-stage biopharmaceutical company, reported a net loss of $11.5 million for the third quarter of 2024, compared to a net loss of $14.3 million for the same period in 2023.
• The company's net loss for the first nine months of 2024 was $44.1 million, an improvement from the $48.3 million loss in the same period of 2023.
• As of September 30, 2024, NextCure had $75.3 million in cash, cash equivalents, and marketable securities.
• The company believes its current funds will support operations into the second half of 2026.
• NextCure is focusing on advancing its LNCB74 antibody-drug conjugate and is seeking partnerships for other programs, including NC410, NC525, NC318, NC181 and NC605.
• A restructuring plan in March 2024 included pausing internal manufacturing and reducing the workforce by approximately 37%.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the reduced losses, extended cash runway, and focus on a promising lead program. However, the company still faces significant risks and challenges, including the need for additional funding and successful clinical trial outcomes.

Positives

• The company's net loss decreased in both the third quarter and the first nine months of 2024 compared to the same periods in 2023.
• NextCure has a solid cash position of $75.3 million, which is expected to fund operations into the second half of 2026.
• The company is focusing on its most promising program, LNCB74, which has shown potent tumor killing in preclinical studies.
• The company is actively seeking partnerships to advance other programs, potentially bringing in additional funding and expertise.

Negatives

• The company continues to operate at a loss, with a net loss of $11.5 million in Q3 2024 and $44.1 million for the first nine months of 2024.
• The company has not generated any revenue from product sales and does not expect to in the foreseeable future.
• The company has paused its internal manufacturing operations, which may impact future development plans.
• The company has reduced its workforce by 37%, which may impact productivity and morale.

Risks

• The company's future success is dependent on the successful development and commercialization of its product candidates, which is subject to significant risks and uncertainties.
• The company may not be able to secure partnerships or additional funding on acceptable terms, which could impact its ability to advance its programs.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The company's restructuring plan may not achieve the desired results, and the company may face challenges in managing its reduced workforce.
• The company is dependent on third parties for manufacturing and clinical trial management, which could lead to delays or other issues.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund its planned operations into the second half of 2026. The company expects to incur substantial expenditures in the foreseeable future as it advances LNCB74 through clinical development, the regulatory approval process and, if approved, commercialization. The company will need substantial additional funding to support its continuing operations and to pursue its development strategy.

Management Comments

• The company is focused on advancing therapies that leverage core strengths in understanding biological pathways and biomarkers.
• The company is prioritizing the development of LNCB74, a B7-H4 targeted ADC.
• The company plans to file an IND application for LNCB74 by year-end and advance into Phase 1.
• The company is seeking partnering or third party financing to advance NC410 in further clinical trials.
• The company is seeking to partner its clinical programs NC525 and NC318 and pursue a partner or third party financing to advance its preclinical non-oncology programs.
• The company believes that both of its non-oncology programs have the potential to file an IND application within twelve to eighteen months if financial support from a partner or third parties is secured.

Industry Context

The company's focus on antibody-drug conjugates (ADCs) and targeted therapies aligns with current trends in the biopharmaceutical industry, where these approaches are gaining traction for cancer treatment. The company's collaboration with LigaChem is also a common strategy in the industry to share development costs and risks. The company's restructuring and prioritization of its pipeline reflects a broader trend in the biotech industry to focus on core assets and extend cash runways.

Comparison to Industry Standards

• NextCure's cash runway into the second half of 2026 is a positive sign, as many biotech companies face funding challenges.
• The company's focus on ADCs is in line with the industry's interest in this modality, with companies like Seagen and ImmunoGen leading the way.
• The company's restructuring and workforce reduction is a common response to financial pressures in the biotech sector, similar to actions taken by companies like Atara Biotherapeutics and Agenus.
• The company's net loss is typical for a clinical-stage biotech company, but the reduction in losses compared to the previous year is a positive trend.
• The company's collaboration with LigaChem is similar to other biotech partnerships, such as the collaboration between BioNTech and Genmab on antibody therapeutics.

Stakeholder Impact

• Shareholders may be encouraged by the reduced losses and extended cash runway, but will be concerned about the need for additional funding and the risks associated with clinical development.
• Employees may be affected by the workforce reduction, but the company's focus on core programs may provide more job security for remaining employees.
• Customers and suppliers may be impacted by the company's restructuring and prioritization of its pipeline.
• Creditors may be concerned about the company's ongoing losses and need for additional funding.

Next Steps

• The company plans to file an IND application for LNCB74 by year-end and advance into Phase 1.
• The company will continue to monitor the four active ovarian cancer and seven active CRC patients in the NC410 study.
• The company will seek partnering or third party financing to advance NC410 in further clinical trials.
• The company will seek to partner its clinical programs NC525 and NC318 and pursue a partner or third party financing to advance its preclinical non-oncology programs.

Key Dates

Keywords

biopharmaceutical, oncology, antibody-drug conjugate, clinical trials, LNCB74, NC410, restructuring, cash runway, partnerships, B7-H4